Claire Torre

Author PubWeight™ 6.51^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.	Blood	2005	1.95
2	A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.	Clin Cancer Res	2010	1.29
3	Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.	Blood	2010	0.93
4	A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.	Biol Blood Marrow Transplant	2004	0.88
5	Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.	Biol Blood Marrow Transplant	2012	0.81
6	Regulation of alloimmune responses by dendritic cell subsets.	Exp Hematol	2008	0.78